Format

Send to

Choose Destination
Cancer Treat Rev. 2017 Feb;53:111-119. doi: 10.1016/j.ctrv.2016.12.010. Epub 2017 Jan 5.

Targeting Epidermal Growth Factor Receptor in triple negative breast cancer: New discoveries and practical insights for drug development.

Author information

1
Developmental Therapeutics Program, Division of Hematology/Oncology, Feinberg School of Medicine, Chicago, USA. Electronic address: ricardo.costa@northwestern.edu.
2
Division of Hematology/Oncology, Feinberg School of Medicine, Chicago, USA.
3
Developmental Therapeutics Program, Division of Hematology/Oncology, Feinberg School of Medicine, Chicago, USA; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, USA.
4
Developmental Therapeutics Program, Division of Hematology/Oncology, Feinberg School of Medicine, Chicago, USA.
5
Departments of Medicine Cancer Research and Therapy Center and School of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.

Abstract

Triple negative breast cancer (TNBC) accounts for 10-20% of cases in breast cancer. Despite recent advances in the treatment of hormonal receptor+ and HER2+ breast cancers, there are no targeted therapies available for TNBC. Evidence supports that most patients with TNBC express the transmembrane Epidermal Growth Factor Receptor (EGFR). However, early phase clinical trials failed to demonstrate significant activity of EGFR-targeted monoclonal antibodies and/or tyrosine kinase inhibitors. Here, we review the recent discoveries related to the underlying biology of the EGFR pathway in TNBC, clinical progress to date and suggest rational future approaches for investigational therapies in TNBC.

KEYWORDS:

Epidermal Growth Factor Receptor; Targeted therapy; Triple negative breast cancer; mTOR

PMID:
28104566
DOI:
10.1016/j.ctrv.2016.12.010
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center